For deep-tech VC funds
Built for funds investing in hard science.
Patent and technical assessment for funds that need to know whether a promising invention can become a company ready for capital.
Who this is for
Deep-tech VC funds. Not generalists.
VentureIP is built for VC funds that invest in deep science and deep engineering. Broad deep-tech coverage, including robotics, semiconductors, biotech, advanced materials, energy and climate, photonics, quantum, and emerging areas as they rise. Not wrapper-AI funds. Not generalist consumer funds. Not law firms.
The problem
Three reasons deep-tech review breaks.
Deep-tech review does not fit a generalist template.
Generic AI workflows miss the technical details that matter. Semiconductors, biotech, advanced materials, and photonics each need sector-specific review before a partner reads the deck.
The decision window is shorter than the assessment cycle.
Rounds price while traditional patent and technical review is still being scheduled. Evidence that arrives after the term sheet arrives too late.
The patent position is hard to read.
Deep-tech deals can break on patent coverage, competing filings, or conflict risk. Generalist analysts read the abstract. We read what the patent actually protects.
Segment specialization
Deep tech, read by people who know the segment.
VentureIP covers deep tech broadly, including active and emerging areas where patent strength, technical readiness, and approval path decide the round. Each segment has its own review method. VentureIP applies the right one.
Segment map
Six active sectors, one evidence standard.
The map keeps segment specificity visible before the page moves into individual cards.
Sector 01
Robotics
Sector 02
Semiconductors
Sector 03
Biotech and bioengineering
Sector 04
Advanced materials
Sector 05
Energy and climate tech
Sector 06
Photonics and quantum
Emerging queue
Coverage rule
If the invention is technically deep and the patent position matters, the method applies.
Segment
Robotics
Actuation, perception, autonomy stacks, and embodied AI. We read both the patent position and whether the system can work outside the lab.
Segment
Semiconductors
Process, materials, chip design, photonics-adjacent. Segment specialists who can read a process flow.
Segment
Biotech and bioengineering
Delivery platforms, protein design, synthetic biology, diagnostics. IP and regulatory-pathway readers in one sweep.
Segment
Advanced materials
Coatings, composites, energy-dense chemistries, nanomaterials. We review scale-up risk and patent coverage together.
Segment
Energy and climate tech
Fusion, batteries, geothermal, hydrogen, carbon capture. Technical review for hardware that has to survive real-world operating conditions.
Segment
Photonics and quantum
Photonic integration, quantum computing, quantum sensing, optics. Deep-science platforms where patent strength can decide the round.
Also active and emerging
We cover emerging deep-tech areas as they move from lab to deployment, including Space and aerospace, Autonomous systems, Neurotechnology, Advanced manufacturing, Nuclear, Agritech and food science, Computational bio, and Hardware-rooted cybersecurity. If the invention is technically deep and the patent position matters, the method applies.
Where we fit
From sourcing to portfolio, with evidence at every stage.
The workflow is useful before partner time, during review, and later when blind market comparisons start to matter.
Stage 01
Sourcing
Screen large inbound pipelines against sector-specific patent and technical evidence.
Stage 02
Screen
Rapid patent and technical readiness check before investing partner time.
Stage 03
Full review
Full assessment: patent landscape, conflict risk, technical readiness, and risk register.
Stage 04
Portfolio
Blind cross-fund comparables and heat map across participating funds.
Why this works
Shared deep-tech deal patterns. Blind across funds.
Participating funds use the same assessment workflow. The resulting comparable-deal data is blind between funds by design. Each fund sees the shape of the market without seeing the other funds' books. Over time, the shared pattern library becomes the advantage.
Founding cohort / By review
Founding access is reviewed for fit, not claimed by speed.
Selection is by review, not first-come. Accepted funds receive Tier 3 access at the 1% founding carry rate.
Put us on your next deep-tech review.
Start a conversation and we will scope the engagement against your pipeline shape.